Intravitreal 4D-150 remained well tolerated at all doses in all patients, with no Grade ≥1 inflammatory cells, hypotony, dose-limiting toxicities, or treatment-related serious adverse events (SAE) during follow-up through 36 weeks.Lower doses (1E10, 6E9 vg/eye) also highly active, with 5 of 10 patients requiring zero or one supplemental anti-VEGF injections and a 71% reduction in mean annualized supplemental anti-VEGF injection rate through 36 weeks.Assessment of outcomes beyond 36 weeks in the 3E10 vg/eye dose cohort showed a durable reduction in supplemental anti-VEGF injections, with 3 of 4 evaluable participants remaining injection-free beyond one year and one patient remaining injection-free during a maximum follow-up of 80 weeks no change in safety profile observed.Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a clinically meaningful reduction in mean central subfield thickness (CST) at 36 weeks in patient population with high anti-VEGF need.

Max yang 4d molecular therapeutics